Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites-Reference-Cited by-同舟云学术

Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites

Published:2001-11 Issue:5-6 Volume:67 Page:279-288
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

Vassilakopoulos T.P.,Angelopoulou M.K.,Siakantaris M.P.,Kontopidou F.N.,Dimopoulou M.N.,Barbounis A.,Grigorakis V.,Karkantaris C.,Anargyrou K.,Chatziioannou M.,Rombos J.,Boussiotis V.A.,Vaiopoulos G.,Kittas C.,Pangalis G.A.

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1034/j.1600-0609.2001.00561.x/fullpdf

Reference59 articles.

1. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD;Canellos;N Engl J Med,1992

2. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD. A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial;Somers;J Clin Oncol,1994

3. Treatment of advanced Hodgkin's disease with chemotherapy - Comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD. A report from the National Cancer Institute of Canada Clinical Trials Group;Connors;J Clin Oncol,1997

4. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results;Viviani;J Clin Oncol,1996

5. MOPP/ABV versus ABVD for advanced Hodgkin's disease: a preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC);Duggan;Proc Am Soc Clin Oncol,1997

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical relevance of cyclooxygenase 2 and vascular endothelial growth factor-A expression in classical Hodgkin lymphoma;The Egyptian Journal of Haematology;2023-10

2. Serum Procalcitonin Levels in Newly Diagnosed Hodgkin Lymphoma: Correlation with Other Inflammatory Biomarkers;Medicina;2022-09-22

3. Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies;Therapeutic Advances in Hematology;2020-01

4. Evaluation of the prognostic importance of c-myc and bcl-2 expressions and the presence of epstein-barr virus in classical hodgkin lymphoma;Turkish Journal of Pathology;2018

5. The Significance of PET/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical Trials;Anticancer Research;2017-10-03